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1. Introduction
  H u m a n  i m m u n o d e f i c i e n c y  v i r u s / A c q u i r e d 
immunodeficiency syndrome (HIV/AIDS) is a growing 
global problem, in terms of its incidence and mortality. 
The current estimated 33.4 million people living with HIV 
and AIDS mortality of 2.0 million has made the HIV/AIDS 
epidemic among the leading causes of death worldwide[1]. 
In Nigeria, epidemiological surveillance of HIV/AIDS 
showed an increasing prevalence from 0.000 001% in 1986 
to 5.8% in 2001, a drop in 2003 to 5.0% and a further slight 
drop in 2005 to 4.4%[2-4]. A recent report has shown that the 
estimated number of AIDS death in Nigeria has increased 
progressively from 42 0000 in 1995 to the 170 000 in 2007[5]. 
Multi-organ involvement by opportunistic infections and 
neoplasms is the major cause of morbidity and mortality in 
people living with HIV/AIDS[6]. People with HIV or AIDS are 
at a greater risk for contracting “opportunistic” diseases 
because these diseases take advantage of the body’s 
lowered defenses.
  Chlamydophila (formerly Chlamydia) pneumoniae (C. 
pneumoniae) is a small, non-motile, Gram-negative and 
obligate intracellular pathogen[7]. It commonly causes 
pharyngitis, bronchitis and atypical pneumonia mainly in 
elderly and debilitated patients but in healthy adults[8-12]; 
and less commonly causes several other illnesses such as 
meningoencephalitis, arthritis, myocarditis, Guillain-Barré 
syndrome, Alzheimer’s disease, fibromyalgia, Chronic 
Fatigue Syndrome, prostatitis, and many others[12-15]. 
  Infection with C. pneumoniae occurs worldwide, especially 
in adults[16], with a reported 40% to 90% prevalence of 
serum antibody to the species[17-19]. It was shown to be 
a frequent cause of pneumonia and other diseases in 
HIV/AIDS patients[12,20,21]. In Nigeria, information on the 
seroprevalence of C. pneumoniae in HIV/AIDS patients is 
lacking or at best scarce. Given the high number of AIDS 
deaths in Nigeria, the second highest in the World, after 
South Africa[5,22], the additional burden of C. pneumoniae 
infections will further increase HIV-related deaths if not 
routinely screened for and checked. The present study aims 
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at the detection of anti-C. pneumoniae IgG antibodies in 
sera of HIV/AIDS patients which attended a Government-
approved Anti-retroviral Treatment (ART) Center to provide 
a basis for the possible inclusion of routine screening for 
anti-C. pneumoniae antibodies and anti-chlamydial agents 
for prevention or treatment of C. pneumoniae infections in 
the National HIV/AIDS Management Plan in Nigeria. 
2. Materials and methods
2.1. Patients and specimen collection
  During the period April 2005 to March 2006, a total of 34 
patients (13 males, 21 females) between the age of 16 and 46 
years old which attended the ART Facility at the National 
Institute for Pharmaceutical Research and Development, 
Abuja were enrolled for the study. These patients, which 
had CD4 lymphocyte counts of 35-1 460 cells/毺L and PCV of 
34-47%, gave their consent in writing, by filling and signing 
a questionnaire administered to them.
  Five milliliters of blood was collected from a vein of each 
of the patients using a sterile syringe, then allowed to 
coagulate at room temperature and serum separated. The 
sera were kept at -20 曟 until required for testing.
2.2. ImmunoComb® Chlamydia Bivalent IgG test
  Detection of anti-CP IgG was done by a solid-phase 
enzyme-linked immunosorbent assay (ELISA) using 
ImmunoComb® Chlamydia Bivalent IgG [Chlamydophila 
trachomatis (C. trachomatis) and C. pneumoniae] kit 
manufactured by Orgenics (Israel). This test kit is a 
quantitative serologic test that uses two distinct strains 
on two differentiated spots: L2 serovar strain (Chlamydia 
trachomatis) and IOL 207 (TWAR) strain (C. pneumoniae). 
The extraction and elimination of the common genus-
specific lipopolysaccharide (LPS) antigenic fraction enables 
the specific and differential diagnosis of C. trachomatis 
and C. pneumoniae infections. The EIA was performed and 
interpreted in accordance with manufacturer’s instructions.
3. Results 
  Anti-C. pneumoniae IgG antibodies were detected in 58.8% 
(20/34) of the patients tested. The detection rate was higher 
among the males (61.5%; 8/13) than the females (57.1%; 
12/21). Patients of the age group 16-30 years had the highest 
detection of anti-C. pneumoniae IgG antibodies (70%; 7/10) 
followed by those of age group > 45 years (66.7%; 2/3) and 
lastly age group 31-45 (52.4%; 11/21).
4. Discussion
  C. pneumoniae can be detected by culturing, antigen 
detection assays (the direct fluorescent antibody assay 
and enzyme immunoassay), serology and molecular 
techniques[23,24]. However, due to the problem of one 
or a combination of cost, availability of testing kits, 
expertise and laboratories, time-demand, sensitivity and 
specificity, serological testing, the “gold standard” being 
the microimmunofluorescence (MIF) test, is currently the 
most widely used tool for routine diagnosis of C. pneumoniae 
infection[24].
  Both IgG and IgA classes of antibodies are generated 
upon C. pneumoniae infection in a patient; but while IgG 
antibodies tend to last for years, the presence of IgA is 
more correlated with an on-going infection or with a recent 
event[16]. Thus, the detection of IgG against C. pneumoniae 
in the sera the HIV/AIDS patients in our study may be 
indicative for a past, recent or active status in acute, chronic 
and recurrent CP infections. Elsewere, a high prevalence of 
antibodies to C. pneumoniae in HIV-positive individuals in 
Thialand has been reported[21]. The decrease in the detection 
rate with age observed in our study is not in agreement with 
earlier data elsewhere that the distribution of seroprevalence 
of C. pneumoniae infection increases with age[23] but agrees 
with a recent report in Thialand[21]. 
  Although ImmunoComb assay for IgG antibodies to C. 
pneumoniae was found to be inferior to those of the MIF, 
the serology gold standard[14], it can be used as a method 
for presumptive serology due to its rapidity and ease of 
performance. Wherever possible, one or more additional 
tests should also be performed to increase the specificity 
of such studies. Thus, further study that employs a larger 
sample population size across the country and uses other 
detection techniques is required to confirm this observation.
Although in a small population size, the detection of anti-C. 
pneumoniae IgG in sera of HIV/AIDS patients attending 
the ART Center in Abuja provides rationale for possible 
inclusion of routine screening for anti-C. pneumoniae 
antibodies (either IgG or IgA) and anti-chlamydial agents in 
the National HIV/AIDS Management Plan in Nigeria.
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